ClinicalTrialsFinder
RecruitingPhase 2NCT06461182

Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma

Ga-68-CXCR4 PET/CT in Detecting, Evaluating Response to Treatment, and Monitoring Risk of Aggressiveness of Indolent B-cell Lymphoma

Sponsor

Koo Foundation Sun Yat-Sen Cancer Center

Enrollment

15 participants

Start Date

Apr 29, 2024

Study Type

INTERVENTIONAL

Conditions

Indolent B-Cell Non-Hodgkin Lymphoma

Summary

This study explores the efficacy of Ga-68-PentixaFor PET/CT in detecting, assessing treatment response, and monitoring the risk of aggressiveness in indolent B-cell lymphoma. The background introduces CXCR4 and discusses its role in cancer research. Currently, FDG-PET is the primary imaging tool for lymphoma staging, but it lacks diagnostic accuracy for low-grade lymphomas. Ga-68-PentixaFor PET demonstrates promising detection capabilities across various lymphomas, suggesting its potential as a superior imaging modality for low-grade lymphomas.

Eligibility

Min Age: 20 YearsMax Age: 100 Years

Inclusion Criteria6

  • The pathological diagnosis is slow-growing lymphoma, such as: marginal-zone B-cell lymphoma, Waldenstrom macroglobulinemia lymphocytic lymphoma, CLL/SLL, mantle cell lymphoma.
  • Have undergone or planned to undergo FDG PET scan for indications including initial staging, therapeutic response evaluation, or follow-up examinations within 3 to 6 months in the clinical observation group.
  • Able to lie flat for at least 30 minutes.
  • Signing the subject consent form.
  • ECOG grade 0-2.
  • The timing of F-18-FDG usage in this trial follows the "Lymphoma Treatment Principles" of our institution.

Exclusion Criteria7

  • Pregnant woman
  • Severe renal impairment (eGRF\< 30ml/min)
  • Known or suspected allergy to radiopharmaceuticals
  • Concurrent or previous diagnosis of malignancies other than lymphoma
  • Inability to undergo the necessary PET scan procedure
  • Refusal or unwillingness to sign the informed consent form
  • Severe medical conditions (severe disabilities, mental disorders)

Interventions

DRUGGa-68-CXCR4

Ga-68-CXCR4 for PET/CT procedure in Indolent B-cell Lymphoma

Locations(1)

Koo Foundation Sun Yat-Sen Cancer Center

Taipei, Beitou, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06461182

Related Trials

SynKIR-310 for Relapsed/Refractory B-NHL

NCT065442655 locations

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

NCT063863157 locations

A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL

NCT0357156827 locations